Cargando…

CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer

BACKGROUND: A previous clinical study in non-small cell lung cancer (NSCLC) patients in Western countries suggested the potential for combination of a first-in-class non-ATP-competitive c-Met inhibitor tivantinib with an epidermal growth factor receptor-tyrosine kinase inhibitor erlotinib. Polymorph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamamoto, N, Murakami, H, Hayashi, H, Fujisaka, Y, Hirashima, T, Takeda, K, Satouchi, M, Miyoshi, K, Akinaga, S, Takahashi, T, Nakagawa, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844902/ https://www.ncbi.nlm.nih.gov/pubmed/24169346 http://dx.doi.org/10.1038/bjc.2013.588

Ejemplares similares

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
por: Azuma, Koichi, et al.
Publicado: (2016)

Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma
por: Wei, Kai, et al.
Publicado: (2019)

Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors
por: Kummar, Shivaani, et al.
Publicado: (2021)

Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107
por: Twardowski, Przemyslaw W., et al.
Publicado: (2017)

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
por: Wu, Zhuo-Xun, et al.
Publicado: (2020)

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
por: Baljevic, Muhamed, et al.
Publicado: (2017)

Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
por: Zhao, Shankun, et al.
Publicado: (2021)

The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis
por: Wang, Yubin, et al.
Publicado: (2023)

Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells
por: Huang, Keqiang, et al.
Publicado: (2018)

Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1
por: Lu, Shuai, et al.
Publicado: (2015)

Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib
por: Agwa, Eberechi S, et al.
Publicado: (2014)

Targeting the Pro-Survival Protein MET with Tivantinib (ARQ 197) Inhibits Growth of Multiple Myeloma Cells()()
por: Zaman, Shadia, et al.
Publicado: (2015)

Development of Tivantinib as Treatment for Hepatocellular Carcinoma
por: Au, Jennifer, et al.
Publicado: (2013)

Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non–small-cell lung cancer: A meta-analysis based on randomized controlled trials
por: Deng, Huan, et al.
Publicado: (2020)

Combination of the c-Met Inhibitor Tivantinib and Zoledronic Acid Prevents Tumor Bone Engraftment and Inhibits Progression of Established Bone Metastases in a Breast Xenograft Model
por: Previdi, Sara, et al.
Publicado: (2013)

Experimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibody
por: Zhuang, Hong-Qing, et al.
Publicado: (2014)

A randomized, double‐blind, placebo‐controlled, phase 3 study of tivantinib in Japanese patients with MET‐high hepatocellular carcinoma
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Application of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study
por: Luo, Guang-li, et al.
Publicado: (2022)

Tivantinib alleviates inflammatory diseases by directly targeting NLRP3
por: Huang, Yi, et al.
Publicado: (2023)

An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
por: Murakami, H., et al.
Publicado: (2014)

CYP2C19 Genotype Is Not Associated With the Risk of Microscopic Colitis
por: DARLINGTON, K. C., et al.
Publicado: (2023)

Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date
por: Pievsky, Daniel, et al.
Publicado: (2016)

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer
por: Camidge, D. Ross, et al.
Publicado: (2023)

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
por: Puzanov, Igor, et al.
Publicado: (2014)

Methodology for clinical genotyping of CYP2D6 and CYP2C19
por: Carvalho Henriques, Beatriz, et al.
Publicado: (2021)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype
por: Helsby, N A, et al.
Publicado: (2008)

Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia
por: Kuenzi, Brent M., et al.
Publicado: (2019)

Correction: Methodology for clinical genotyping of CYP2D6 and CYP2C19
por: Henriques, Beatriz Carvalho, et al.
Publicado: (2022)

Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals
por: Isaza, Carlos, et al.
Publicado: (2007)

The efficacy and safety of tivantinib in the treatment of solid tumors: a systematic review and meta-analysis
por: Zhang, Hao, et al.
Publicado: (2017)

Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping
por: Fontana, Pierre, et al.
Publicado: (2013)

The impact of CYP2C19 genotype on phenoconversion by concomitant medication
por: de Jong, Laura M., et al.
Publicado: (2023)

Global variation in CYP2C8–CYP2C9 functional haplotypes
por: Speed, William C, et al.
Publicado: (2009)

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
por: Santoro, A, et al.
Publicado: (2013)

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse
por: Sanchez-Spitman, A. B., et al.
Publicado: (2021)

Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer
por: Broggini, Massimo, et al.
Publicado: (2013)

Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma
por: Xiang, Qingfeng, et al.
Publicado: (2015)

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
por: Tolaney, Sara M., et al.
Publicado: (2015)

Evaluating the Extent of Reusability of CYP2C19 Genotype Data among Patients Genotyped for Antiplatelet Therapy Selection
por: Beitelshees, Amber L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_smhaaaccf1ckoe21des9rtvnf8